RGene Therapeutics Inc., Targeted Genetics deal

TGEN completed its previously announced acquisition of privately held RGene for 3.64 million shares of TGEN (see BioCentury April 22). TGEN closed at $4.437 on Friday. TGEN acquires non-viral gene delivery technology that will complement its viral technologies. RGene has a gene therapy product in Phase I trials for cancer. ...